See more : Beijing Jingxi Culture & Tourism Co.,Ltd (000802.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Senseonics Holdings, Inc. (SENS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senseonics Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- StoneX Group Inc. (SNEX) Income Statement Analysis – Financial Results
- Orbital Corporation Limited (OEC.AX) Income Statement Analysis – Financial Results
- Uflex Limited (UFLEX.BO) Income Statement Analysis – Financial Results
- Shankara Building Products Limited (SHANKARA.NS) Income Statement Analysis – Financial Results
- QSAM Biosciences, Inc. (QSAM) Income Statement Analysis – Financial Results
Senseonics Holdings, Inc. (SENS)
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.39M | 16.39M | 13.68M | 4.95M | 21.30M | 18.91M | 6.37M | 332.00K | 38.00K | 0.00 | 17.00K |
| Cost of Revenue | 19.30M | 13.66M | 14.49M | 22.32M | 40.75M | 27.06M | 9.76M | 660.00K | 118.00K | 0.00 | 5.00K |
| Gross Profit | 3.09M | 2.73M | -811.00K | -17.37M | -19.45M | -8.15M | -3.39M | -328.00K | -80.00K | 0.00 | 12.00K |
| Gross Profit Ratio | 13.81% | 16.63% | -5.93% | -350.90% | -91.30% | -43.07% | -53.11% | -98.80% | -210.53% | 0.00% | 70.59% |
| Research & Development | 48.75M | 39.72M | 27.22M | 20.41M | 38.43M | 31.86M | 30.74M | 26.35M | 18.25M | 12.88M | 13.79M |
| General & Administrative | 0.00 | 0.00 | 21.54M | 20.80M | 23.23M | 19.84M | 15.34M | 13.02M | 9.81M | 5.73M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 7.62M | 20.55M | 49.56M | 27.73M | 6.86M | 2.74M | 792.00K | 95.00K | 0.00 |
| SG&A | 29.94M | 31.63M | 29.15M | 41.35M | 72.78M | 47.57M | 22.19M | 15.76M | 10.60M | 5.82M | 5.01M |
| Other Expenses | 0.00 | -102.00K | -174.00K | -311.00K | -511.00K | -321.00K | 176.00K | 25.00K | 26.00K | 0.00 | 0.00 |
| Operating Expenses | 78.69M | 71.35M | 56.37M | 61.76M | 111.21M | 79.43M | 52.93M | 42.11M | 28.85M | 18.70M | 18.80M |
| Cost & Expenses | 97.99M | 85.02M | 70.86M | 84.08M | 151.96M | 106.49M | 62.69M | 42.77M | 28.85M | 18.70M | 18.81M |
| Interest Income | 5.36M | 1.82M | 243.00K | 175.00K | 1.93M | 2.00M | 135.00K | 80.00K | 9.00K | 0.00 | 10.00K |
| Interest Expense | 11.11M | 18.70M | 16.72M | 16.17M | 12.20M | 8.28M | 3.10M | 1.60M | 1.10M | 191.00K | 0.00 |
| Depreciation & Amortization | 1.28M | 985.00K | 1.24M | 1.14M | 1.00M | 270.00K | 227.27K | 155.00K | 118.00K | 189.00K | 220.00K |
| EBITDA | -48.01M | 161.81M | -284.52M | -157.86M | -99.41M | -85.42M | -55.77M | -42.17M | -28.66M | -18.51M | -18.57M |
| EBITDA Ratio | -214.40% | -408.23% | -417.65% | -1,859.91% | -622.43% | -454.17% | -875.18% | -12,702.71% | -75,418.42% | 0.00% | -109,229.41% |
| Operating Income | -75.60M | -68.63M | -57.18M | -79.13M | -130.66M | -87.58M | -56.31M | -42.43M | -28.81M | -18.70M | -18.79M |
| Operating Income Ratio | -337.66% | -418.74% | -418.15% | -1,598.91% | -613.41% | -463.06% | -883.62% | -12,781.02% | -75,821.05% | 0.00% | -110,523.53% |
| Total Other Income/Expenses | 15.21M | 210.75M | -245.29M | -96.04M | 15.11M | -6.39M | -2.79M | -1.50M | -1.07M | -183.00K | 10.00K |
| Income Before Tax | -60.39M | 142.12M | -302.48M | -175.17M | -115.55M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Income Before Tax Ratio | -269.73% | 867.16% | -2,211.88% | -3,539.46% | -542.46% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| Income Tax Expense | 0.00 | 18.70M | 15.31M | 15.86M | 10.69M | 6.39M | 2.79M | 1.50M | 1.07M | 183.00K | 0.00 |
| Net Income | -60.39M | 142.12M | -317.78M | -191.02M | -126.23M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Net Income Ratio | -269.73% | 867.16% | -2,323.81% | -3,859.85% | -592.62% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| EPS | -0.11 | 0.30 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| EPS Diluted | -0.11 | -0.11 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| Weighted Avg Shares Out | 567.97M | 467.95M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
| Weighted Avg Shares Out (Dil) | 567.97M | 618.21M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming Gilmartin Group...
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
Let's be honest – penny stocks priced at less than a buck hold an irresistible appeal. Even a small investment could potentially lead to insane returns.
Best Penny Stocks To Buy Now? 7 Under $1 To Watch
Penny stocks priced under $1 per share have attracted a dedicated following among traders seeking massive returns. While penny stocks are inherently high-risk investments, the potential reward with these low-priced shares is exponentially higher compared to traditional blue chip stocks.
Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it has entered into a $50 million...
3 Top Penny Stocks To Buy Now According To Insiders
The allure of penny stocks is undeniable. Their low price point, combined with the potential for high returns, makes them a tantalizing option for investors.
Senseonics Holdings (SENS) Reports Q2 Loss, Misses Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Senseonics Holdings, Inc. (SENS) Q2 2023 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Tim Goodnow - President and CEO Rick Sullivan - CFO Conference Call Participants Colin Clark - Stifel Sam...
Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter ended June 30,...
Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its second quarter 2023...
Best Penny Stocks To Buy Now? 6 Under $1 To Watch Now
Today's penny stock market is brimming with high-volatility stocks. That especially relates to those that fall into the category of the cheapest penny stocks.
Source: https://incomestatements.info
Category: Stock Reports